Relay Therapeutics is trading at $20.07 (4.6% up) in after-hours trading as investors continue to respond to positive clinical data and analyst price target hikes.
- The move extends bullish sentiment from strong Phase 2 ReInspire results for zovegalisib and promising interim breast cancer data for RLY-2608.
- Multiple analysts have raised price targets following the data releases, building on the momentum from a 4.1% gain recorded on July 17, 2026.